Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose

Psychopharmacology

Volumn 196, Issue 1, 2008, Pages 51-62

  Páleníček, Tomáš ^a   Balíková, Marie ^b   Bubeníková Valešová, Věra ^a   Horáček, Jiří ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Locomotion; Mescaline; Pharmacokinetics; Rats; Sensorimotor gating

Indexed keywords

MESCALINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY STIMULATION; BRAIN HOMOGENATE; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; GAS CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; STARTLE REFLEX; STIMULUS RESPONSE; TIME; WISTAR RAT;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HABITUATION, PSYCHOPHYSIOLOGIC; HALLUCINOGENS; INHIBITION (PSYCHOLOGY); INJECTIONS, SUBCUTANEOUS; MALE; MESCALINE; METABOLIC CLEARANCE RATE; MOTOR ACTIVITY; ORIENTATION; RATS; RATS, WISTAR; STARTLE REACTION; TIME FACTORS;

EID: 38149090980     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0926-5     Document Type: Article

References (79)

1. Ahn HS, Makman MH (1979) Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: regional differences. Brain Res 162:77-88
2. Balikova M (2005) Nonfatal and fatal DOB (2,5-dimethoxy-4- bromoamphetamine) overdose. Forensic Sci Int 153:85-91
3. Bankson MG, Cunningham KA (2001) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846-852
4. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152
5. Baselt RC (2002) Disposition of toxic drugs and chemicals in man, 6th edn. Biomedical Publications, Foster City, California (CA)
6. Bourn WM, Keller WJ, Bonfiglio JF (1978) Psychoactivity of normacromerine in animals. Life Sci 23:1175-1184
7. Browne RG, Harris RT, Ho BT (1974) Stimulus properties of mescaline and N-methylated derivatives: difference in peripheral and direct central administration. Psychopharmacologia 39:43-56
8. Bubenikova V, Votava M, Horacek J, Palenicek T (2005) Relation of sex and estrous phase to deficits in prepulse inhibition of the startle response induced by ecstasy (MDMA). Behav Pharmacol 16:127-130
9. Carder B, Sbordone R (1975) Mescaline treated rats attack immobile targets. Pharmacol Biochem Behav 3:923-925
10. Carey RJ, DePalma G, Damianopoulos E, Muller CP, Huston JP (2004) The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berl) 177:46-54
11. Charalampous KD, Kinross-Wright J (1963) Hallucinogens. Tools for research of therapeutic agents. Tex Med 59:848-852
12. Charalampous KD, Walker KE, Kinross-Wright J (1966) Metabolic fate of mescaline in man. Psychopharmacologia 9:48-63
13. Chen NH, Reith ME (1995) Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 64:1585-1597
14. Cohen I, Vogel WH (1970) An assay procedure for mescaline and its determination in rat brain, liver and plasma. Experientia 26:1231-1232
15. Davis M (1987) Mescaline: excitatory effects on acoustic startle are blocked by serotonin2 antagonists. Psychopharmacology (Berl) 93:286-291
16. Davis WM, Bedford JA, Buelke JL, Guinn MM, Hatoum HT, Waters IW, Wilson MC, Braude MC (1978) Acute toxicity and gross behavioral effects of amphetamine, four methoxyamphetamines, and mescaline in rodents, dogs, and monkeys. Toxicol Appl Pharmacol 45:49-62
17. Eilam D, Golani I (1989) Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behav Brain Res 34:199-211
18. EMCDDA (2004a) Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxembourg
19. EMCDDA (2004b) Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxembourg
20. EMCDDA Joint action on NSD (2005) Summary by substance according to the EWS Progress and Yearly Reports-2004
21. Fink H, Morgenstern R, Oelssner W (1979) Psychotomimetics potentiate locomotor hyperactivity induced by dopaminergic drugs. Pharmacol Biochem Behav 11:479-482
22. Fiorella D, Palumbo PA, Rabin RA, Winter JC (1995) The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents. Psychopharmacology (Berl) 119:239-245
23. Foltz RL, Fentiman AF Jr, Foltz RB (1980) GC/MS assays for abused drugs in body fluids. NIDA Res Monogr 32:1-198
24. French Identification System for Synthetic Drugs of OFDT (SINTES) (2003) Collection and toxicological analysis in the framework of SINTES
25. Geyer MA, Petersen LR, Rose GJ, Horwitt DD, Light RK, Adams LM, Zook JA, Hawkins RL, Mandell AJ (1978) The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle. J Pharmacol Exp Ther 207:837-847
26. Geyer MA, Light RK, Rose GJ, Petersen LR, Horwitt DD, Adams LM, Hawkins RL (1979) A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl) 65:35-40
27. Geyer MA, Russo PV, Masten VL (1986) Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25:277-288
28. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154
29. Giroud C, Augsburger M, Rivier L, Mangin P, Sadeghipour F, Varesio E, Veuthey JL, Kamalaprija P (1998) 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J Anal Toxicol 22:345-354
30. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84:413-429
31. Golani I, Benjamini Y, Eilam D (1993) Stopping behavior: constraints on exploration in rats (Rattus norvegicus). Behav Brain Res 53:21-33
32. Gorelick DA, Bridger WH (1977) Facilitation and disruption by mescaline and 3,4-dimethoxyphenylethylamine of shock avoidance in rats. Psychopharmacology (Berl) 52:157-163
33. Hardman HF, Haavik CO, Seevers MH (1973) Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 25:299-309
34. 2A receptor ligands. Arch Pharm (Weinheim) 336:155-158
35. Harris RA, Snell D, Loh HH (1978) Effects of d-amphetamine, monomethoxyamphetamines and hallucinogens on schedule-controlled behavior. J Pharmacol Exp Ther 204:103-117
36. Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32:976-991
37. Hirschhorn ID, Winter JC (1971) Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli. Psychopharmacologia 22:64-71
38. Johansson C, Jackson DM, Zhang J, Svensson L (1995) Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol Biochem Behav 52:649-654
39. Kaur P, Ahlenius S (1997) Potentiation of DOI-induced forward locomotion in rats by (-)-pindolol pretreatment. J Neural Transm 104:605-614
40. Koch M (1999) The neurobiology of startle. Prog Neurobiol 59:107-128
41. Krebs-Thomson K, Geyer MA (1996) The role of 5-HT(1A) receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats. Behav Pharmacol 7:551-559
42. Krebs-Thomson K, Paulus MP, Geyer MA (1998) Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339-351
43. Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA (2006) The roles of 5-HT(1A) and 5-HT (2) receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) 189:319-329
44. Laing R, Siegel JA (2003) Hallucinogens. A forensic drug handbook. Academic, London
45. Lát J (1973) The analysis of habituation. Acta Neurobiol.Exp (Wars.) 33:771-789
46. Lejeune F, Millan MJ (2000) Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors. Eur J Neurosci 12:3265-3275
47. Lindner W, Wainer IW (1998) Requirements for initial assay validation and publication in J. Chromatography B. J Chromatogr B Biomed Sci Appl 707:1-2
48. Mittman SM, Geyer MA (1991) Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology (Berl) 105:69-76
49. Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE (1997) Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 40:2997-3008
50. Musacchio JM, Goldstein M (1967) The metabolism of mescaline-14-C in rats. Biochem Pharmacol 16:963-970
51. National Drug Intelligence Center (2001) Information Bulletin: 2C-B (Nexus) Reappears on the Club Drug Scene. http://www.usdoj.gov/ndic/pubs0/665/ 665t.htm
52. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181
53. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001) Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25:565-575
54. Owen S (2005) New drug discovered in Nevada County raid. http://www.news10.net/storyfull2.aspx?storyid=14931
55. Palenicek T, Bubenikova V, Votava M, Horacek J (2005a) Účinky MDMA, LSD a psilocinu na lokomoci potkana [The effects of MDMA, LSD and Psilocin on locomotion of the rat]. Adiktologie 5:120-130
56. Palenicek T, Votava M, Bubenikova V, Horacek J (2005b) Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 86:546-553
57. 2C receptor SB242084 on rat's locomotion in animal models of psychosis]. Adiktologie 10:16-19
58. Penders J, Verstraete A (2006) Laboratory guidelines and standards in clinical and forensic toxicology. Accredit Qual Assur 11:284-290
59. Peters FT, Drummer OH, Musshoff F (2007) Validation of new methods. Forensic Sci Int 165:216-224
60. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000) 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237
61. Sbordone RJ, Wingard JA, Elliott MK, Jervey J (1978) Mescaline produces pathological aggression in rats regardless of age or strain. Pharmacol Biochem Behav 8:543-546
62. Sbordone RJ, Wingard JA, Gorelick DA, Elliott ML (1979) Severe aggression in rats induced by mescaline but not other hallucinogens. Psychopharmacology (Berl) 66:275-280
63. Scheline R (1978) Mammalian metabolism of plant xenobiotics. Academic, London
64. Sethy VH, Winter JC (1973) Effect of chronic treatment with mescaline upon tissue levels of the drug. Experientia 29:571-572
65. Silva MT, Calil HM (1975) Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia 42:163-171
66. Silva F, Heath RG, Rafferty T, Johnson R, Robinson W (1960) Comparative effects of the administration of Taraxein, d-LSD, mescaline, and psilocybin to human volunteers. Compr Psychiatry 1:370-376
67. Sipes TA, Geyer MA (1994) Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 33:441-448
68. Sipes TA, Geyer MA (1995a) 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology (Berl) 117:41-48
69. Sipes TE, Geyer MA (1995b) DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. Behav Pharmacol 6:839-842
70. Sipes TE, Geyer MA (1997) DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761:97-104
71. Smythies JR, Sykes EA (1964) The effect of mescaline upon the conditioned avoidance response in the rat. Psychopharmacologia 6:163-172
72. Speck LB (1957) Toxicity and effects of increasing doses of mescaline. J Pharmacol Exp Ther 119:78-84
73. Spinella M (2001) The Psychopharmacology of herbal medicine. Plant drugs that alter mind, brain, and behavior. The MIT Press, Cambridge
74. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194-215
75. Sykes EA (1986) Mescaline-induced motor impairment in rats, assessed by two different methods. Life Sci 39:1051-1058
76. Trulson ME, Crisp T, Henderson LJ (1983) Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors. Eur J Pharmacol 96:151-154
77. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495-507
78. Wing LL, Tapson GS, Geyer MA (1990) 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl) 100:417-425
79. Yamamoto T, Ueki S (1975) Behavioral effects of 2,5-dimethoxy-4- methylamphetamine (DOM) in rats and mice. Eur J Pharmacol 32:156-162